Our groundbreaking KREX® protein folding technology was developed at Cambridge University in the UK by Professor Jonathan Blackburn, Sengenics founder and chief scientific officer. Since forming Sengenics in 2008, our team of distinguished scientists continues to evolve our technology, expanding into new applications addressing a range of critical unmet needs. Our unique technology is supported by a robust IP estate, with a massive addressable market.
Sengenics has successfully collaborated on landmark discovery projects with 9 of the top 10 pharmaceutical companies, as well as innovative pharma and biotech startups. We collaborate with leading academic research institutions and disease foundations, and we work closely with industry groups such as the Personalized Medicine Coalition (PMC), Human Proteome Organization (HUPO) and the Foundation for the National Institutes of Health (FNIH), and Sengenics is also an affiliate company of the Milner Therapeutics Institute.
More than 160 companies and institutions have used our KREX® technology platform to advance their research and product development.
projects completed
assays run
publications using Sengenics technology
